Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

J&J’s Bengay, Sanofi’s Icy Hot May Cause Rare Burns, FDA Says

Sept. 13 (Bloomberg) -- Johnson & Johnson’s Bengay and Sanofi’s Icy Hot are among topical pain relievers that have been associated with a rare risk of serious burns, U.S. regulators said today.

The over-the-counter pain-relieving creams, lotions and patches are linked to 43 cases of burns on the application site, the Food and Drug Administration said in a safety announcement. The cases were identified in a search of the FDA’s adverse event reporting system and medical literature.

The majority of second- and third-degree burns occurred with the use of products containing menthol as the single active ingredient or having both menthol and methyl salicylate, the FDA said. Few cases involved a capsaicin-containing product. Patients who experience pain, swelling or blistering of the skin should stop using the product, the agency said.

“When applied to the skin, the products produce a local sensation of warmth or coolness; they should not cause pain or skin damage,” the FDA said in the announcement.

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.